Literature DB >> 10050703

Course of the international Normalized Ratio in response to oral vitamin K1 in patients overanticoagulated with phenprocoumon.

F J Penning-van Beest1, F R Rosendaal, D E Grobbee, E van Meegen, B H Stricker.   

Abstract

Oral vitamin K1 is used for the treatment of excessive anticoagulation. Detailed information on changes in the International Normalized Ratio (INR) in response to vitamin K1 is not available. We therefore measured the INR for the first 7 d following the oral intake of 1-5 mg of vitamin K1 in 24 patients routinely treated with phenprocoumon who had an INR > or =6.0 at presentation. On the first 2 d after administration of vitamin K1, the mean INR decreased by 40% and 23% respectively. After day 2, the day-to-day proportional change in the mean INR depended on the dose of vitamin K1 and varied from a decrease of 12% to an increase of 21%. On day 7 the mean INR was higher than on day 2 in three out of five treatment groups. Between day 2 and day 7, in general, 32% of the patients had an INR value within the target zone, 25% had an INR value > or =6.0 and 8% had an INR value <2.0. These findings suggest that our routine treatment of overanticoagulation in patients on phenprocoumon should be intensified to improve its efficacy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10050703     DOI: 10.1046/j.1365-2141.1999.01196.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

Review 1.  Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure.

Authors:  Andrea Lee; Mark Crowther
Journal:  J Thromb Thrombolysis       Date:  2011-04       Impact factor: 2.300

Review 2.  Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.

Authors:  Mike Ufer
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 3.  Anticoagulant therapy in special circumstances.

Authors:  T G DeLoughery
Journal:  Curr Cardiol Rep       Date:  2000-01       Impact factor: 2.931

4.  Obesity is associated with a slower response to initial phenprocoumon therapy whereas CYP2C9 genotypes are not.

Authors:  Cordula Meyer zu Schwabedissen; Vera Mevissen; Fabian Schmitz; Seth Woodruff; Georg Langebartels; Thomas Rau; Klaus Zerres; Rainer Hoffmann; Jan R Ortlepp
Journal:  Eur J Clin Pharmacol       Date:  2006-07-18       Impact factor: 2.953

Review 5.  Low-dose oral vitamin K therapy for the management of asymptomatic patients with elevated international normalized ratios: a brief review.

Authors:  Sarah E Wilson; Henry G Watson; Mark A Crowther
Journal:  CMAJ       Date:  2004-03-02       Impact factor: 8.262

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.